Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - UK
The Guardian - UK
Business
Julia Kollewe

Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration
The drug semaglutide is marketed as Wegovy for obesity and Ozempic for diabetes. Novo Nordisk has been struggling to keep up with demand for both. Photograph: Reuters

Strong sales of diabetes and weight loss drugs Ozempic and Wegovy have prompted the Danish pharmaceutical company Novo Nordisk to raise its 2024 profit forecast to up to £15.3bn, with supply shortages starting to ease.

Europe’s most valuable company, whose stock market value exceeds the size of the Danish economy, has struggled to keep up with runaway demand for the two weight-loss jabs.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.